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Abstract
Methamphetamine (METH) abuse in conjunction with human immunodeficiency virus (HIV) exacerbates neuropathogenesis
and accelerates neurocognitive impairments in the central nervous system (CNS), collectively termed HIV Associated
Neurocognitive Disorders (HAND). Since both HIV and METH have been implicated in altering the synaptic architecture, this
study focused on investigating alterations in synaptic proteins. Employing a quantitative proteomics approach on
synaptosomes isolated from the caudate nucleus from two groups of rhesus monkeys chronically infected with simian
immunodeficiency virus (SIV) differing by one regimen, METH treatment, we identified the neuron specific Na
+/K
+-ATPase
alpha 1 isoform 3 (ATP1A3) to be up regulated after METH treatment, and validated its up regulation by METH in vitro.
Further studies on signaling mechanisms revealed that the activation of ATP1A3 involves the extracellular regulated kinase
(ERK) pathway. Given its function in maintaining ionic gradients and emerging role as a signaling molecule, changes in
ATP1A3 yields insights into the mechanisms associated with HAND and interactions with drugs of abuse.
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Introduction
The neurological, motor and cognitive impairments in AIDS
collectively termed HIV Associated Neurocognitive Disorders
(HAND) or neuroAIDS encompasses a broad range of neurolog-
ical abnormalities including asymptomatic neurocognitive impair-
ment; HIV associated mild cognitive motor disorder and the most
severe disease, HIV associated dementia [1,2]. The increasing
usage of drugs of abuse, in particular methamphetamine (METH)
abuse poses a significant co-morbid factor in HIV-infection due to
the mutual association with risky behaviors such as intravenous
injection [3] and risky sexual behavior with multiple partners
[4,5]. Clinical studies have documented evidence that HIV
positive individuals dependent on METH have a higher rate of
neuropsychological impairment than those that do not use METH
or METH users that are not HIV infected [6]. This overlap in the
HIV infected and METH using population raises the potential
importance of an interaction between these agents that affects the
brain. While the neurotoxicity resulting from HIV infection
involves toxic viral proteins or inflammatory mediators produced
by infected and/or activated macrophages and activated glial cells
[7,8] METH amplifies this activation cascade [9,10] as well as
directly affecting the neurons [11].
Although several advances have been made in identifying
molecules that have provided valuable insights into mechanisms of
neuropathogenesis, only minimal information exits on synaptic
changes associated with HIV/METH induced neurodegeneration.
Synapses are key structures involved in neurotransmission and
neuroplasticity. Both HIV and METH lead to alterations in the
synaptic architecture thus leading to neurodegeneration [12]. In
order to investigate differential patterns in synaptic proteins, we
isolated synaptosomes, which represent isolated synapses contain-
ing the pre and post synaptic components, from the caudate
nucleus from rhesus monkeys chronically infected with SIV and
differing by one regimen, METH treatment. The caudate was
chosen as it is a target of both HIV and METH. Quantitative
proteomics identified the neuron specific Na
+/K
+-ATPase alpha 3
isoform 3 (ATP1A3) to be up regulated after METH treatment
amongst a panel of synaptic proteins showing differential
expression. Studies were then performed to ascertain the role of
ATP1A3 in HIV/METH induced CNS dysfunction.
Materials and Methods
Ethics statement
Materials used in these studies were from animal work
performed under IACUC approval (from the Scripps Research
Institute, 07-0067). Animal welfare was maintained by following
NIH (Public Health Service, Office of Laboratory Animal Welfare)
and USDA guidelines by trained veterinary staff and researchers
under Association for Assessment and Accreditation of Laboratory
Animal Care certification, insuring standards for housing, health
care, nutrition, environmental enrichment and psychological well-
being. These met or exceeded those set forth in the Guide for the
Care and User of Laboratory Animals from the National Research
Council of the US National Academy of Sciences. All efforts were
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anesthesia with ketamine, xylazine, and phenobarbital at necrop-
sy.
Rhesus macaques, SIV infection and METH treatment
Full details of the METH treatment and course of infection
have been described in our previous publication [13]. Briefly six
rhesus monkeys (Macaca mulatta), free of type D simian retroviruses,
Cercopithecine Herpesvirus 1, simian T-cell leukemia virus type 1,
and SIV, were infected with an in vivo serial passage derivative of
SIVmac251 [14,15]. At 19 weeks of infection, animals were
matched for viral load, and three were treated with an escalating
dose regimen of METH injected intramuscularly (5 week ramp-up
followed by 18 week maintenance at 25 mg/kg/week); the other
three animals received PBS injections on the same schedule. All
animals were sacrificed at 42 weeks post infection, before the
development of AIDS, and tissues harvested following PBS
perfusion under lethal anesthesia.
Isolation of Synaptosomes
Synaptosomes were isolated using a discontinuous sucrose
density gradient by differential centrifugation using a standard
isolation procedure [16]. 250 mg of the caudate nucleus from each
animal was homogenized in 10 volumes of ice-cold buffered
sucrose (0.32 M sucrose, 5 mM HEPES containing complete
EDTA-free protease inhibitor cocktail (Roche Applied Science,
Indianapolis, IN) with twelve strokes in a dounce homogenizer
using a Wheaton overhead stirrer at 250 rpm. The homogenate
was centrifuged at 1,0006 g for 10 min at 4uC to yield the post
nuclear supernatant. The post nuclear supernatant was centri-
fuged at 12,0006 g for 20 min at 4uC to yield the crude
synaptosomal pellet. The crude synaptosomal pellet was gently
dissolved in the buffered sucrose and layered over the discontin-
uous sucrose gradient comprising of 0.6, 0.8 and 1.2 M sucrose
from top to bottom and centrifuged at 145, 0006g for 90 min at
4uC. The purified synaptosomes were isolated from the interface
of 0.8 and 1.2 M layers, diluted with 10 volumes of buffered
sucrose and washed at 145, 0006g for 30 min at 4uC. The pellet
was carefully resuspended in the buffered sucrose and protein
concentration was determined using BCA kit (Pierce, Pittsburg,
PA) with BSA as a standard.
iTRAQ labeling
Isobaric Tag for Relative and Absolute Quantitation (iTRAQ)
labeling was performed as described in our earlier studies [17,18].
A pooled sample was made of the synaptosomal fractions from all
samples. 100 mg protein from each individual sample and the pool
were digested with trypsin and labeled separately using the
iTRAQ (Applied Biosystems, Foster City, CA) standard protocols
for the 8-plex kit. The saline group was labeled with 113, 114, 115,
METH group with 116, 117, 118 and the pool with 121. Samples
from each group were combined together and subjected to peptide
purification followed by OFFGEL fractionation.
Peptide purification and OFFGEL fractionation
Labeled samples were subjected to cleanup using a Waters
Oasis MCX cartridge (Waters, Milford, MA), a mixed mode
cation exchange cartridge packed with materials containing both
hydrophobic properties and negatively charged groups. 1 mL of
0.2% formic acid was added to each sample to obtain a final pH of
3. Each MCX cartridge was equilibrated by slowly passing 1 mL
of 1:1 methanol: water across the cartridge. The sample was
applied at a flow rate of 1 drop per second followed by subsequent
wash with 1 mL of 5% methanol, 0.1% formic acid followed by
1 mL of 100% methanol. The bound peptide was eluted with
freshly prepared elution buffer (50 ml of 28% NH4OH, 950 mlo f
methanol), dried in a speed vac and stored at 280C until subjected
to OFFGEL fractionation.
Peptide fractionation was performed using the 3100 OFFGEL
Fractionator (Agilent Technologies, Santa Clara, CA) following
the manufacturer’s protocol. The device was set up for the 12
fractions separation by using 13-cm-long IPG gel strip with a
linear pH gradient ranging at 3–10. 100 mg of peptide digest was
resuspended with focusing buffer to a final volume of 1.8 mL.
150 mL of this sample was loaded in each of the 12 wells. The
sample was focused using the recommended method for OFFGEL
peptides 12 wells fractionation with a maximum current of 50 mA.
The focusing was stopped after total voltage reached 50 kVh.
During focusing, oil was added to the electrodes to prevent any
evaporation effect. After focusing, 50 to 200 ml of sample was
recovered for each well and transferred in individual micro tubes.
For maximum recovery of the peptides, 200 ml of (49:50:1)
water:methanol:formic acid was added to each well, incubated for
15 min without voltage, dried in a speed vac and resuspended with
the corresponding sample. Corresponding peptides fractions were
concentrated by vacuum centrifugation prior to spotting onto a
MALDI plate followed by LC-MS/MS analysis.
Tempo LC and MALDI-TOF/TOF
The Tempo LC MALDI robotic spotting system equipped with
a C18 reversed phase capillary column (AB Sciex, Foster City, CA)
was used to further fractionate peptides from OFFGEL fractions,
followed by data acquisition using 4800 MALDI TOF/TOF (AB
Sciex) as previously published [19]. Briefly, using an in-house
packed C18 column to separate fractions by HPLC gradient, LC
fractions were spotted onto MALDI 1232-spot format plates, with
a spotting interval of 24 s and applying 2.8 kV plate voltage. Data
was acquired from LC MALDI spot fractions using 4800 MALDI
TOF/TOF equipped with a 200 Hz repetition rate Nd:YAG
laser. Spectra from a total of 800 laser shots was accumulated for
each TOF MS spectrum between 800 and 4000 m/z. Data-
dependent MS/MS mode was operated using CID gas (air) and
2 kV collision energy. Programmed laser stop conditions were
employed for the accumulation of MS/MS spectra from 800 to
4000 laser shots.
Data Analysis
TOF MS and MS/MS spectra were analyzed using Protein
Pilot v.2.0.1 software, which utilizes the Paragon scoring algorithm
[20]. Search parameters included: iTRAQ 8plex (peptide labeled)
sample type, iodoacetemide cys alkylation, trypsin digest, biolog-
ical modifications ID focus and thorough search effort. The
protein FASTA database used for searches was a concatenated
‘‘target-decoy’’ version of Macaca subset of the NCBInr database
(20090731).
Cell culture
Rat striatal neurons from embryonic day 18 Sprague Dawley
rat pups were cultured in Neurobasal media containing B27
(Invitrogen, Carlsbad, CA). For western blot analysis, cells were
plated at a density of 1610
6 per well onto a 6-well plate and
2.5610
5 cells per well for immunolabeling, in a 24-well plate
containing coverslips. All treatments were performed after
culturing 8 days in vitro (DIV).
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Cell viability was measured by 3-(4,5-dmethylthiazol-2-yl)-2,5-
diphenyl Tetrazolium bromide (MTT) method. Rat striatal
neurons were seeded in 96-well plates and exposed to various
concentrations of METH for 24 h. Post treatment, MTT
tetrazolium salt dissolved in Hank’s balanced salt solution at a
final concentration of 5 mg/ml was added to each well and
incubated at 37uC till the formation of formazan crystals. The
medium was carefully aspirated from each well and 200 mlo f
dimethyl sulfoxide was added to dissolve the formazan crystals and
the absorbance of each well was obtained using a plate counter at
test and reference wavelengths of 570 nm and 630 nm, respec-
tively.
Immunofluorescence
Prior to double labeling, both the control and METH treated
rat striatal neurons were fixed in 4% paraformaldehyde. After
three washes with PBS, cells were permeabilized with 0.25%
Tween-20 in PBS for 20 min at room temperature and washed
twice with PBS. Cells were incubated in 10% normal goat serum
with 0.25% Tween-20 in PBS for 30 min at room temperature
and then incubated with anti-ATP1A3 (1:50 Santa Cruz) at 4uC
overnight. After incubation with fluorescence-labeled secondary
antibody (1:100, donkey anti-goat IgG, Invitrogen) for 1 h at room
temperature, the second primary antibody anti-MAP2 (1:500,
Sternberger Monoclonals, Lutherville, MD) was added at 4uC
overnight. After incubation with second secondary antibody
(1:100, chicken anti-mouse IgG, Invitrogen), cells were washed
and mounted with Prolong Gold with DAPI and analyzed by
microscopy (Carl Zeiss, USA). For staining with Synaptophysin,
cells earlier incubated with anti-ATP1A3 were incubated in 10%
normal goat serum with 0.25% Tween-20 in PBS for 30 min at
room temperature and then incubated with anti-SYP (1:500 Santa
Cruz) at 4uC overnight. Cells were washed and mounted with
Prolong Gold with DAPI and analyzed by microscopy (Carl Zeiss,
USA)
Pharmacological inhibitors
The specific ERK1/2 inhibitor U0126, JNK inhibitor
SP600125 and p38 inhibitor SB203580 were purchased from
Sigma (St. Louis, MO). For cell signaling experiments, cells were
pre-treated with 20 mM each with U1026, SP600125 and
SB203580 for 1 h followed by TNF-a and IFN-c (6 h) and/or
METH treatment (15 min) and analyzed by western blot analysis.
Western blot analysis
SDS-PAGE electrophoresis was performed using NuPAGE gel
system (Invitrogen) in 6% Tris-Glycine (ATP1A3) and 4–12%
gradient gels (pERK1/2 and pJNK) under reducing conditions.
For western blot analyses, 10 mg of rat striatal cell lysate were
loaded per lane. Electrophoresis followed by transfer and
immunodetection was performed as previously described [21].
Nonspecific antibody binding was blocked using 5% nonfat dried
milk for 1 hr at room temperature. Immunoblotting was carried
out with antibodies against ATP1A3 (1:2500, Santa Cruz
Biotechnology, Santa Cruz, CA), phosphorylated ERK1/2
(1:500, Cell Signaling Technology, Danvers, MA), phopshorylated
JNK (1:500, Cell Signaling Technology) followed by secondary
antibody (1:50,000 HRP conjugated anti goat IgG for ATP1A3
and 1:5000 HRP conjugated anti rabbit for pERK1/2 and pJNK
respectively; GE Healthcare, Little Chalfont, UK). Blots were
developed with 1:1 solution of Super Signal West Pico Chemilu-
minescent Substrate and Luminol/Enhancer (Thermo Fisher
Scientific, Rockford, IL, USA).
Statistics
Data represented are from three independent experiments using
the tests described in the text and figure legends. Differences were
considered significant at p,0.05. Tests were performed using
Prism software (GraphPad Software Inc., San Diego, CA) for
Macintosh.
Results
This study comprised of six rhesus monkeys chronically infected
with SIV with one group receiving chronic METH treatment
mimicking human METH administration patterns both in
frequency and treatment [13]. Since our goal was to examine
the processes leading to CNS disease instead of the end-result of
severe disease, animals were sacrificed prior to development of
AIDS. To gain mechanistic clues associated with METH mediated
CNS dysfunction, we employed a global quantitative mass
spectrometry based proteomics approach by subjecting synapto-
somal proteins isolated from the two groups on a LC-MALDI-
TOF-MS/MS approach. A total of 890 proteins were identified
(Table S1) of which 31 proteins were differentially expressed
between the two groups. Since the differences observed in this
study were subtle yet significant, we set a cutoff change of 1.2 as
the cutoff. This criterion identified a total of eight proteins of
which four were up regulated and four down regulated in the
METH treated group (Table 1). Among the four up regulated
proteins, we identified two transporters (glial affinity glutamate
transporter +1.28 fold) and sodium/potassium/calcium exchanger
+1.28 fold) and two isoforms of the Na
+/K
+ ATPase (NKA)
family- alpha 3 subunit (+1.21 fold) and beta 1 subunit (+1.28 fold).
Amongst the down-regulated proteins identified included enzymes
aldehyde dehydrogenase (21.31 fold), phosphoinositide-specific
phospholipase C beta 1 isoform (21.23 fold), Moesin (21.26 fold)
and the immunoglobulin heavy chain V (21.2 fold).
The identification of Na
+/K
+ ATPase alpha 3 subunit
(ATP1A3) which was up regulated in the METH treated group
was intriguing given its role in maintaining neuronal homeostasis
and its neuronal localization. The NKA utilize .50% of the total
cell’s energy and the increase seen in our study could lead to a
substantial difference in energy utilization and thus can impact
neural homeostasis. In order to examine whether METH itself can
increase the expression of ATP1A3 at the protein level, we isolated
and cultured primary rat striatal neurons and subjected them to
METH treatment. While numerous animal and in vitro studies
utilize a high concentration, neurotoxic dosing of METH, we
wanted to mimic a more physiological concentration where
neuronal death is not prominent acutely. We first assessed
neuronal cell viability over broad range of METH concentrations.
Results from MTT assay showed that concentrations of 500 mM
or greater were toxic (**p,0.01 for 500 mM and ***p,0.001 for
1000 and 2000 mM) and thus a dose of 250 mM was used for all
subsequent experiments (Figure 1A). This concentration is in the
range documented from other published clinical studies that have
measured METH levels in blood, urine or tissue samples of
METH abusers [22–28]. Next, we found that 250 mM METH
treatment of rat striatal neurons led to a significant increase in
ATP1A3 expression. This was demonstrated both by western blot
analysis (Figure 1B) and immunofluorescence, which revealed an
increase in ATP1A3 expression in neurons after METH
treatment, evident in both the soma and neuronal processes
(Figures 2A and 2B). Thus not only does METH treatment in vivo
Role of ATP1A3 in HAND
PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e37604lead to increased ATP1A3 expression, METH treatment ex vivo
reveals a direct distinct response in the neurons through up
regulation of ATP1A3.
We next examined the potential role of brain HIV infection,
which in conjunction with METH leads to neuronal damage.
Though HIV does not infect the neurons, the ensuing damage to
neurons and their subsequent degeneration, is via macrophages
[29], microglia [30,31] and astrocytes [32,33] with the subsequent
release of viral proteins and proinflammatory cytokines. Studies
from other groups including ours have documented a role for the
increased expression of proinflammatory cytokines, TNF-a and
IFN-c in CNS tissues during HIV infection and associated
pathophysiology of HAND [34–36]. To recapitulate the ensuing
cascade of neuronal damage occurring in the brain in vitro,w e
treated rat striatal neurons with proinflammatory cytokines TNF-a
and IFN-c followed by METH treatment for 24 h. Western blot
analysis revealed an increase of ATP1A3 expression and the
expression was further augmented with METH treatment when
neurons were treated with a combination of TNF-a and IFN-c
(Figure 3). Taken together these data point towards a potential
involvement of the virus-induced inflammation in the brain, which
in presence of METH leads to further increase in the expression of
ATP1A3.
Emerging studies have documented the role of ATP1A3 as a
signaling molecule involving the mitogen activated protein kinase
(MAPK) family [37]. Also, both METH and HIV have been
shown to activate members of the mitogen activated protein kinase
(MAPK) family including the extracellularly regulated kinase 1/2
Table 1. Synaptic proteins differentially regulated between the two groups of monkeys.
Protein identified Fold change p-value
Solute carrier family 1 (glial high affinity glutamate transporter), member 3 isoform 9 +1.28 0.014
Solute carrier family 24 (sodium/potassium/calcium exchanger), member 2 isoform 1 +1.28 0.038
Na
+/K
+ -ATPase beta 1 subunit isoform 4 +1.25 0.02
Na
+/K
+ -ATPase alpha 3 subunit 1 +1.21 0.01
Aldehyde dehydrogenase 1A1 isoform 2 21.31 0.015
Moesin 21.26 0.013
Similar to phosphoinositide-specific phospholipase C beta 1 isoform a 21.23 0.049
Similar to Ig heavy chain V-II region SESS precursor 21.2 0.002
Unpaired student t-test was used to determine the significance.
doi:10.1371/journal.pone.0037604.t001
Figure 1. MTT assay showing viability of cells post treatment with varying amounts of METH for 24 h. **p,0.01, ***p,0.001 (A). (B)
Representative western blot confirming up regulation of ATP1A3 in rat striatal neurons treated with indicated concentrations of METH for 24 h as
compared to controls. (C) Bar graphs showing significant increase in ATP1A3 expression post METH treatment versus control. Data represented as
Mean 6 SEM of three independent experiments. *p,0.05.
doi:10.1371/journal.pone.0037604.g001
Figure 2. Primary rat striatal neurons stained for levels and
distribution of ATP1A3 after 250 mM METH treatment for 24 h
along with MAP2 staining for neuronal structure. (A) and with
synaptic marker synaptophysin (B). DAPI was used to stain cell nucleus.
Cells treated with METH show an increase and redistribution of ATP1A3
along the neuronal processes indicated by arrowheads and in the nerve
terminals (inset). Scale bar=10 mm.
doi:10.1371/journal.pone.0037604.g002
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Western blot analysis of lysates from METH treated rat striatal
neurons showed a time-dependent activation of both pERK1/2
and pJNK with a peak expression at 15 min post treatment with
METH (Figure S1, p,0.01 for pERK1/2 and p,0.05 for pJNK
versus control). To further confirm involvement of the specific
pathways in the induction of ATP1A3, neurons were pre-treated
for 1 h with specific pharmacological inhibitors: U1026 for
ERK1/2, SP600125 for JNK and SB203580 for p38, followed
by METH treatment for 15 min. The increase in expression of
ATP1A3 was significantly abrogated with pretreatment with
U1026 (p,0.01 versus METH treated cells) but not SP600325
or SB203580, thus implicating the involvement of the ERK1/2
pathway (Figure 4), which was indeed activated by METH (Figure
S1). Having ascertained the implication of the ERK1/2 pathway,
we hypothesized if both the virus and drug induced expression of
ATP1A3 can be attenuated using the ERK1/2 inhibitor U1026.
Pretreatment of neurons for 1 h with U1026 followed by cytokines
treatment for 6 h and later in presence and absence of METH
treatment for 15 min revealed a significant block in the cytokine 6
METH induced increase in ATP1A3 expression (Figure 5; p,0.05
versus cytokine+METH treated group). Together, these data
implicate a role of ATP1A3 in HIV/METH induced CNS
dysfunction and that this involves the ERK1/2 pathway.
Discussion
In this study, we hypothesized that a quantitative iTRAQ based
proteomics approach would allow us to identify differential protein
fingerprints in the brain reflecting the effect of METH treatment in
SIVinfected monkeys, modelingHIVinfectionof humans and drug
abuse. Profiling of synaptosomes isolated from the caudate nucleus
of the two groups of monkeys identified several synaptic proteins
which were differentially expressed, of which we focused on the
neuron specific Na/K-ATPase alpha 3 subunit (ATP1A3), which
was up regulated after METH treatment. In vitro studies confirmed
that it is up regulated by METH as well as proinflammatory
cytokines typically produced during HIV infection in the brain.
ATP1A3, which is a critical component of the Na/K-ATPase
complex carries out active transport of sodium and potassium
across the cell membrane and maintains the chemical gradients of
these ions. These gradients are of fundamental importance and are
Figure 3. Western blot analysis on rat striatal neurons pre-treated with indicated cytokines (10 ng each) for 6 h followed by METH
treatment for 24 h showing increased ATP1A3 expression compared to METH only and cytokine only treatments. (M – METH, I –
Interferon-c, T – TNF-a). Bar graphs showing significant increase in ATP1A3 expression post treatment with the cytokines. Data represented as Mean
6 SEM of three independent experiments. *p,0.05, **p,0.01, ***p,0.001 versus METH treatment.
doi:10.1371/journal.pone.0037604.g003
Figure 4. Western blot analysis on rat striatal neurons pre-treated with ERK1/2 JNK and p38 inhibitors U1026, SP600125, and
SB203580 respectively followed by METH treatment shows U1026 blocks the METH-induced increase in ATP1A3 expression. (A) but
SP600125 or SB203580 do not (B, C). Data represented as Mean 6 SEM of three independent experiments. **p,0.01 versus control, ##p,0.01
versus METH treatment.
doi:10.1371/journal.pone.0037604.g004
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regulation of cell volume, osmotic activity, transport of neurotrans-
mitters across the plasma membrane and excitability of neuronal
cells [38]. The in vivo effects of reductions in ATP1A3 have been
studied in humans and mice. Genetic studies have identified that
mutations in ATP1A3 are linked with rapid-onset dystonia
Parkinsonism in humans [39]. In mouse mutagenesis studies, a
dysfunctional allele of ATP1A3 was produced that was lethal when
homozygous due to epileptic seizures [40]. Hetereozygous mutant
mice showed hyperactivity, spatial learning and memory deficits,
and increased locomotion induced by METH treatment [41]. It is
hypothesized that a decrease in ATPase activity leads to
pronounced levels of ATP availability and rendering the animals
hyperactive. However in our case, over expression of ATP1A3 is
found, pointing to a higher consumption of ATP, potentially
impacting energy homeostasis in individuals who are HIV+ and use
METH. Though the fold change in ATP1A3 expression seen
between the groups is subtle, at the synaptic level, given the large
role NKA play in neuronal energetics such subtle alterations could
impact dynamics of neurotransmission.
The synapse is a key functional unit in the brain important in
regulating neurotransmission and thus it is plausible that both HIV
and METH could impact the dynamics of neurotransmission. An
earlier study examined synaptosomal proteins from the neocortex of
HIV-infected decedents with AIDS and HIV encephalitis. In this
study, an increased expression of immunoproteasome subunits was
found that was inversely related with the brain HIV viral load [42].
Clearly further examination of synapses, key in neuronal function,
can continue to provide important information regarding the effects
of HIV, drugs of abuse, and other neurological disorders.
Our study has revealed that METH acts through MAPKs to
increase ATP1A3 expression. Interestingly recent studies have
identified ATP1A3 as a significant signal transducing molecule
itself, signaling through MAPKs [37]. Activation of the MAPK
ERK1/2 has mostly been linked to cell survival, proliferation and
differentiation given their activation by mitogens and some cell
survival factors [43–45]. However, activation of ERKs has also
been implicated in neuronal death in certain in vitro models of
neurotoxicity [46–49]. Thus the possibility exists that a feedback
loop exists, in which METH signaling through MAPKs increase
ATP1A3, which then itself helps further increase MAPK signaling.
Neurons are highly specialized and polarized cells with large
energy dependency that consume vast amounts of ATP. Impor-
tantly, neuronal transmission via release of neurotransmitters into
the synaptic cleft is ATP dependent. Central to this regulation is
the Na
+/K
+-ATPase that maintains the intracellular homeostasis
with a tight regulation of Na
+ and K
+ ions. Imbalances in the
intracellular currents especially sodium currents could severely
impact the ion gradient and subsequent effect on ion channels.
There is little yet emerging evidence on alterations in brain energy
metabolism in HIV patients and who are dependent on METH.
An earlier study employing proton magnetic resonance spectros-
copy showed a decrease in the levels of the brain metabolites N-
acetyl aspartate and an increase in myo-inositol levels in the brains
of HIV+ individuals with a chronic history of METH abuse [50].
In another study, METH exposure resulted in mitochondrial
oxidative damage and caused dysfunction of primary human T
cells [51]. A more recent study demonstrated that METH
exposure impairs glucose uptake and metabolism in human
neurons and astrocytes suggesting that deprivation of glucose-
derived energy may contribute to neurotoxicity of METH abusers
[52]. It is thus reasonable to hypothesize that alterations in energy
metabolism induced by METH could further be augmented in
synergy with the virus and thereby leading to neurodegeneration.
Given the synaptic localization of ATP1A3 and its role in
maintaining neuronal homeostasis, an increase in its expression by
METH treatment could potentially impact the dynamics of
neurotransmitter release. Further in vitro and in vivo studies in
model systems would allow the examination of this possibility.
Supporting Information
Figure S1 A time course increase in phosphorylated
forms of ERK1/2 (A) and JNK (B) in rat striatal neurons
treated with METH. Data represented asMean6 SEMofthree
independent experiments. *p,0.05, **p,0.01 versus control.
(TIF)
Table S1 Complete list of synaptic proteins identified
between the two groups of monkeys. Unpaired student t-
test was used to determine the significance.
(XLS)
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